Suggestions
Matthew Kinn
SVP - Business Development & Corporate Initiatives at Recursion | Member of Recursion Executive Leadership Team | Ex-BCG Principal | Ex-Investment Banking
Matthew Kinn is a senior executive at Recursion, a biotechnology company that operates at the intersection of science and technology. He currently serves as the Senior Vice President of Business Development & Corporate Initiatives.13
Professional Background
Prior to joining Recursion, Kinn had a notable career in consulting and finance:
- He was a Principal at the Boston Consulting Group's San Francisco office, where he advised biopharma and tech clients on strategic decisions, including portfolio optimization, product launch forecasting, and mergers and acquisitions.2
- Earlier in his career, he worked at UBS Investment Bank in New York, supporting M&A and capital market transactions across various industries.2
Education
Kinn has a strong educational background in business and finance:
- MBA from Northwestern University's Kellogg School of Management
- Undergraduate degrees in finance and economics from the University of Virginia's McIntire School of Commerce2
Role at Recursion
As part of Recursion's executive leadership team, Kinn plays a crucial role in the company's growth and strategic initiatives. Recursion is a rapidly expanding organization with approximately 500 employees, whom they call "Recursionauts".3 The company focuses on decoding biology to radically improve lives, utilizing a blend of life sciences and computational expertise.
Personal Interests
Outside of his professional life, Matthew Kinn enjoys outdoor activities such as trail running and cross-country skiing. He also values spending time with his family.2
Highlights
Our earnings report has just been announced! Hear more about it live on our social feeds today at 3:00PM MT where our Co-Founder and CEO Chris Gibson will be taking us through the highlights of the report in our first L(earnings) call. You’ll be able to ask questions, hear our recap of 2023, and learn more about our plans for 2024. #techbio $RXRX
Could not be more proud and excited to announce that Recursion has entered into a truly transformational collaboration with Roche & Genentech to initiate up to 40 programs in neuroscience and oncology! This deal represents a future-looking model of technology enabled target and drug discovery, leveraging machine learning and massive biological datasets to identify novel targets and advance medicines to patients. https://lnkd.in/gvhR5nww
